Additionally, studies with IRE1 and ATF6 in MASLD are warranted to determine the effects of IRE1 or ATF6 inhibitors on MASLD and to identify new targeted drugs for this scenario. This evidence concerns the gene ATF6 and metabolic dysfunction-associated steatotic liver disease.